Physician profile
Nirav Y Raval
NPI 1962401331
$176,291.67
in general payments reported to CMS, 2019-2025
24 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,127 · 2020: $9,692 · 2021: $19K · 2022: $23K · 2023: $49K · 2024: $45K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $65K · Honoraria: $31K · Travel and Lodging: $12K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,212.50 |
| Honoraria | $30,800.00 |
| Travel and Lodging | $12,316.88 |
| Food and Beverage | $10,130.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $99,906.01 | 2019-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $62,852.27 | 2020-2025 | Optimizer, Optimizer |
| Abbott Laboratories | $7,157.97 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Freestyle Libre 2 |
| Medtronic Vascular, INC. | $2,627.68 | 2019 | |
| Medtronic, INC. | $1,514.37 | 2024-2025 | Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Micra |
| Abiomed | $971.39 | 2019-2025 | Impella |
| United Therapeutics Corporation | $257.85 | 2019-2025 | |
| Boston Scientific Corporation | $190.95 | 2025 | Farapulse |
| Nuwellis, INC. | $149.96 | 2025 | Aquadex Smartflow Console |
| Procyrion, INC. | $140.72 | 2025 | Aortix System |
| Astrazeneca Pharmaceuticals LP | $121.82 | 2025 | Wainua |
| Pfizer INC. | $80.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $54.31 | 2021-2022 | |
| Scpharmaceuticals INC. | $45.79 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.41 | 2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $30.65 | 2025 | Attruby |
| Tetraphase Pharmaceuticals, INC. | $30.20 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.01 | 2025 | Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.86 | 2025 | Lifevest |
| Amgen INC. | $21.07 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $19.35 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.00 | 2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $14.37 | 2025 | Camzyos |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.